middle.news
Clarity Clears Final Follow-Up Hurdle Before 2027 Prostate Cancer Readout
8:33am on Thursday 19th of November, 2026 AEDT
•
Biotechnology and Pharmaceuticals
Read Story
Clarity Clears Final Follow-Up Hurdle Before 2027 Prostate Cancer Readout
8:33am on Thursday 19th of November, 2026 AEDT
Key Points
Final follow-up assessments completed for all AMPLIFY participants
Phase III trial targets recurrent prostate cancer after initial treatment
Coprimary endpoints cover correct detection rate and positive predictive value
Topline AMPLIFY and CLARIFY data expected in the first half of 2027
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clarity Pharmaceuticals (ASX:CU6)
OPEN ARTICLE